Gritstone bio

A cancer immunotherapy company developing next-generation, personalized cancer therapeutics

Gritstone bio is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. Gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and deep financial backing to tackle fundamental challenges at the intersection of cancer genomics, immunology, and immunotherapy design. The company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer.

IPO in 2018 (NASDAQ: GRTS)
Year of Investment
Life Sciences
Bay Area, California